Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation Journal Article
| Authors: | Melica, G.; Preston, E.; Palazzo, M.; Seier, K.; Malard, F.; Cho, C.; Devlin, S. M.; Maloy, M.; Borrill, T.; Maslak, P.; Shah, G. L.; Perales, M. A. |
| Article Title: | Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation |
| Abstract: | Myeloablative T cell depleted (CD34-selected) hematopoietic cell transplantation (HCT) is associated with less acute and chronic graft versus host disease (GVHD). We aimed to examine vaccine responses in relation to immune reconstitution and post HCT rituximab administration in this population. This single center retrospective study included 251 patients with hematological malignancies who received a first CD34-selected HCT between 2012 and 2015. Of 251 patients, 190 were alive 1 year after HCT. Among the entire population, 77 (30.7%) patients were vaccinated. After vaccine administration, 35/44 (80%), 30/75 (40%), 27/36 (75%), 33/65 (51%), 34/51 (51%), 22/28 (79%) and 20/34 (59%) of evaluable patients had protective antibody titers for haemophilus influenzae type B (Hib), Pneumococcus, Tetanus, Diphtheria, Pertussis, hepatitis A (HAV), and hepatitis B (HBV) respectively. Responders to the pneumococcal vaccine had a higher CD45RA T cell count than non responders, with 12/18 patients (66.7%) vs 11/32 (34.4%) p = 0.04. For pneumococcal vaccine, there was also a trend to higher total lymphocyte B cell count in responders vs non responders p = 0.06. Rituximab post HCT was given to 59/251 (23.5%) patients. No difference was found in immune reconstitution patterns for rituximab use between vaccine responders and not. Recipients of CD34-selected HCT may respond to vaccination, and T and B cell subsets could be useful to predict vaccine response. © The Author(s), under exclusive licence to Springer Nature Limited 2024. |
| Keywords: | adolescent; adult; cancer chemotherapy; controlled study; aged; middle aged; retrospective studies; young adult; major clinical study; myeloproliferative disorder; hepatitis b; rituximab; antineoplastic agent; t lymphocyte; cd34 antigen; multiple myeloma; pneumococcus vaccine; hematopoietic stem cell transplantation; retrospective study; b lymphocyte; acute leukemia; hematologic malignancy; myelodysplastic syndrome; whole body radiation; hematologic neoplasms; vaccination; drug response; transplantation conditioning; bone marrow transplantation; ex vivo study; hepatitis b vaccine; pneumococcal infection; antigens, cd34; graft recipient; lymphocyte count; predictive value; drug use; hematologic disease; cd45ra antigen; diphtheria pertussis tetanus vaccine; antibody titer; pertussis; diphtheria; tetanus; poliomyelitis vaccine; immune reconstitution; posttransplant lymphoproliferative disease; chronic leukemia; procedures; poliomyelitis; haemophilus influenzae type b vaccine; humans; human; male; female; article; hepatitis a vaccine; hepatitis a; mismatched unrelated donor; matched related donor; matched unrelated donor; vaccinee; cd34 selected myeloablative allogeneic hematopoietic cell transplantation; haemophilus influenzae infection; unvaccinated person |
| Journal Title: | Bone Marrow Transplantation |
| Volume: | 59 |
| Issue: | 5 |
| ISSN: | 0268-3369 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2024-05-01 |
| Start Page: | 625 |
| End Page: | 629 |
| Language: | English |
| DOI: | 10.1038/s41409-024-02232-3 |
| PUBMED: | 38351281 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Miguel-Angel Perales -- Source: Scopus |
